USP19 polyclonal antibody

The deubiquitinylating enzyme USP19 is induced in skeletal muscle atrophy in response to numerous catabolic stimuli, including cancer, fasting, diabetes, and glucocorticoids. Loss of USP19 interferes with the growth of L6 myoblasts through its modulation of the transcription of major myofibrillar proteins.

USP19 regulates cell growth, partly through indirect control of p27Kip1 degradation in the G1 phase of the cell cycle. Since a number of cancers are associated with enhanced degradation of p27Kip1, the overexpression of USP19 may also be a pathogenetic mechanism of the disordered cell growth in cancer and a potential novel therapeutic target for its treatment.

In addition USP19 has been shown to be a tail anchored DUB, localised to the ER, suggesting a role in the turnover of ERAD substrates and to be targeted by the unfolded protein response.

USP19 is expressed in a wide range of tissues and is localised to the cytoplasm and endoplasmic reticulum.